Quick summary
Heptapeptide-7 is a synthetic seven-amino-acid peptide with EGF-like activity derived from HB-107, stimulating both keratinocyte proliferation and fibroblast collagen synthesis. It is a dual-action cosmeceutical targeting dermal regeneration, stretch marks, and age-related skin thinning.
Overview
Heptapeptide-7 is a synthetic seven-amino-acid peptide fragment derived from HB-107, a wound-healing peptide with EGF-like (epidermal growth factor) activity. It is used in cosmetic formulations targeting dermal regeneration, stretch mark improvement, and age-related skin thinning. The peptide stimulates both keratinocyte and fibroblast activity, making it a dual-action skin-signaling compound.
Mechanism of action
Heptapeptide-7 exerts EGF-mimetic activity by binding to signaling pathways that regulate keratinocyte proliferation and migration. Microarray analysis of HP-7-treated dermal keratinocytes shows upregulation of cell division, growth factor expression, and extracellular matrix genes. The peptide also stimulates fibroblast proliferation and collagen synthesis, and enhances cell-to-cell communication pathways involved in wound healing and dermal regeneration. These combined effects support skin thickness, elasticity, and repair following environmental damage or stretch-related stress.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| dermal regeneration / stretch mark reduction | topical | 1–5 % | once or twice daily | Applied to areas of concern such as abdomen, thighs, or periorbital skin. Consistent daily use recommended. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Ex vivo studies demonstrate that Heptapeptide-7 promotes keratinocyte proliferation and migration and enhances fibroblast collagen production. Microarray data show upregulation of ECM and growth factor gene networks. Clinical and in vivo studies are limited; most evidence is from in vitro cosmetic ingredient research. Marketed primarily for stretch mark prevention and menopausal skin improvement. No published RCTs as of 2026.[1][2]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Heptapeptide-7 for synergistic effects.
Legal status
OTC cosmetic ingredient. Used in topical serums and body creams. No regulatory restrictions in EU, US, or major markets.
Sourcing & access
Research compound
Heptapeptide-7 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Heptapeptide-7, also known as HP-7, is a synthetic seven-amino-acid peptide derived from HB-107, a wound-healing peptide with EGF-like activity. It is used in cosmetic formulations targeting dermal regeneration, stretch mark improvement, and age-related skin thinning, acting as a dual-action signal on both keratinocytes and fibroblasts to support skin thickness, elasticity, and repair.
Heptapeptide-7 acts via EGF-mimetic signaling. Microarray analysis of HP-7-treated keratinocytes shows upregulation of cell division, growth factor expression, and extracellular matrix gene networks. The peptide simultaneously stimulates fibroblast proliferation and collagen synthesis and enhances intercellular communication pathways involved in wound healing, combining epidermal and dermal regenerative signals in a single ingredient.
Heptapeptide-7 is an over-the-counter cosmetic ingredient with no regulatory restrictions in the EU, US, or major markets, and it is not classified as a drug. It is generally well tolerated in topical serums and body creams, with only rare local irritation reported. No clinical randomized controlled trials have been published as of 2026, so long-term safety data in humans remains limited.
Heptapeptide-7 is marketed primarily for stretch mark prevention, menopausal skin improvement, and general anti-aging treatment of thinning or photodamaged skin. Finished cosmetic formulations typically include 1 to 5 percent active peptide applied once or twice daily to areas of concern such as the abdomen, thighs, and periorbital region, with consistent daily use recommended for cumulative effect.